Isovaleric Acidemia Market to Witness Growth by 2032, Estimates DelveInsight | Amgen, Replimune, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, VCNBiosciences

April 06 15:32 2023
Isovaleric Acidemia Market to Witness Growth by 2032, Estimates DelveInsight | Amgen, Replimune, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, VCNBiosciences
Isovaleric Acidemia Market

(New York, USA) DelveInsight’s “Isovaleric Acidemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Isovaleric Acidemia, historical and forecasted epidemiology as well as the Isovaleric Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Isovaleric Acidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Isovaleric Acidemia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Isovaleric Acidemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Isovaleric Acidemia market.


Request for a Free Sample Report @ Isovaleric Acidemia Market Forecast


Some facts of the Isovaleric Acidemia Market Report are:

  • According to DelveInsight, Isovaleric Acidemia market size is expected to reach USD XX Million by 2032.
  • Leading Isovaleric Acidemia companies working in the market are Amgen, Replimune Group Inc., Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, VCNBiosciences, DNAtrix and others.
  • In June 2022, Mead Johnson & Company, LLC announced that it had been completely merged with Reckitt Benckiser Group plc (RB). With Reckitt Benckiser plc groups’ good innovation and marketing processes, it was expected that the Mead Johnson brand and business would continue to boom.
  • On February 17, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines, announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen build up, is being evaluated for the potential oral treatment of patients with late-onset Pompe disease.


Isovaleric Acidemia Overview

Isovaleric acidemia is a hereditary metabolic disorder, caused by a change (mutation) in the gene encoding the enzyme isovaleryl-CoA dehydrogenase, resulting in deficient or absent activity. This enzyme is responsible for helping break down leucine, an amino acid, and its deficiency leads to a buildup of chemicals in the blood that cause symptoms.

In the United States and some developed countries, isovaleric acidemia is routinely identified by newborn screening through a blood test called tandem mass spectrometry, often designated as MS/MS. In other countries, the diagnosis must be suspected clinically before it can be diagnosed. Laboratory studies that can be useful in symptomatic patients include checking for high levels of acid and ketones (ketoacidosis) in blood, high levels of glycine in the blood or urine (hyperglycinemia and hyperglycinuria), high levels of ammonia (hyperammonemia), or low levels of certain white blood cells (neutropenia), platelets (thrombocytopenia) or all blood cell types (pancytopenia). The diagnosis is then confirmed by DNA testing. Less commonly, certain types of cells from the body (white blood cells, skin cells) may be sampled from the patient and tested to confirm decreased or deficient activity of the enzyme isovaleryl-CoA dehydrogenase.


Learn more about Isovaleric Acidemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @


Isovaleric Acidemia Market 

The Isovaleric Acidemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Isovaleric Acidemia market trends by analyzing the impact of current Isovaleric Acidemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Isovaleric Acidemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Isovaleric Acidemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Isovaleric Acidemia market in 7MM is expected to witness a major change in the study period 2019-2032.


Request a sample and discover more about the report offerings @


Isovaleric Acidemia Epidemiology 

The Isovaleric Acidemia epidemiology section provides insights into the historical and current Isovaleric Acidemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Isovaleric Acidemia market report also provides the diagnosed patient pool, trends, and assumptions. 


Explore more about Isovaleric Acidemia Epidemiology @


Isovaleric Acidemia Drugs Uptake

This section focuses on the uptake rate of the potential Isovaleric Acidemia drugs recently launched in the Isovaleric Acidemia market or expected to be launched in 2019-2032. The analysis covers the Isovaleric Acidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Isovaleric Acidemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Isovaleric Acidemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Isovaleric Acidemia Pipeline Development Activities

The Isovaleric Acidemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Isovaleric Acidemia key players involved in developing targeted therapeutics.


Isovaleric Acidemia Therapeutics Assessment

Major key companies are working proactively in the Isovaleric Acidemia Therapeutics market to develop novel therapies which will drive the Isovaleric Acidemia treatment markets in the upcoming years are Amgen, Replimune Group Inc., Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, VCNBiosciences, DNAtrix and others.


Learn more about the emerging Isovaleric Acidemia therapies & key companies @


Isovaleric Acidemia Report Key Insights

1. Isovaleric Acidemia Patient Population

2. Isovaleric Acidemia Market Size and Trends

3. Key Cross Competition in the Isovaleric Acidemia Market

4. Isovaleric Acidemia Market Dynamics (Key Drivers and Barriers)

5. Isovaleric Acidemia Market Opportunities

6. Isovaleric Acidemia Therapeutic Approaches

7. Isovaleric Acidemia Pipeline Analysis

8. Isovaleric Acidemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Isovaleric Acidemia Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Isovaleric Acidemia Competitive Intelligence Analysis

4. Isovaleric Acidemia Market Overview at a Glance

5. Isovaleric Acidemia Disease Background and Overview

6. Isovaleric Acidemia Patient Journey

7. Isovaleric Acidemia Epidemiology and Patient Population

8. Isovaleric Acidemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Isovaleric Acidemia Unmet Needs

10. Key Endpoints of Isovaleric Acidemia Treatment

11. Isovaleric Acidemia Marketed Products

12. Isovaleric Acidemia Emerging Therapies

13. Isovaleric Acidemia Seven Major Market Analysis

14. Attribute Analysis

15. Isovaleric Acidemia Market Outlook (7 major markets)

16. Isovaleric Acidemia Access and Reimbursement Overview

17. KOL Views on the Isovaleric Acidemia Market

18. Isovaleric Acidemia Market Drivers

19. Isovaleric Acidemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States